The Myc/Max/Mad network of transcriptional regulatory proteins plays an essential role in cell proliferation, growth, apoptosis, and dierentiation. Whereas Myc proteins aect cell cycle progression positively, Mad proteins are negative regulators of cell proliferation. It has been shown in several in vitro systems that Mad proteins antagonize c-Myc functions. In this report we describe the inhibition of tumor cell outgrowth in vivo by Mad1 expression. Transformed cell lines were generated by co-transfection of c-myc, c-H-ras, and a chimeric mad1ER construct into primary rat embryo cells (MRMad1ER cells). Activation of Mad1 by 4-Hydroxy-Tamoxifen (OHT) resulted in abrogation of telomerase activity, reduced cloning eciency, and decreased proportion of cells in S phase. Injection of MRMad1ER cells into syngenic rats induced aggressively growing tumors after a short latency period. This tumor growth was inhibited by OHT-treatment of animals, with the extent of inhibition correlating with the amount of OHT injected. No eect of OHT on tumor growth was observed with similarly transformed Myc/Ras cell lines which did not express Mad1ER. These data demonstrate that Mad1 is able to suppress Myc/Ras-mediated transformation under in vivo conditions.
Introduction
The development and homeostasis of a multicellular organism is guided by four cellular processes: proliferation, growth (i.e. increase in cell mass), dierentiation, and apoptosis. Compelling evidence indicates that the Myc/Max/Mad network plays a key role in the regulation of each of these (for review see Henriksson and LuÈ scher, 1996; Facchini and Penn, 1998; Johnson et al., 1999; Eilers, 1999; Grandori et al., 2000; LuÈ scher, 2001) . The proteins of this network belong to the basic/ helix ± loop ± helix/leucine-zipper (bHLHZip) class of transcription factors. Max plays a central role for network function because of its abundance and its versatility to form homodimers and to associate with Myc (c-, N-, and L-Myc), Mad (Mad 1, Mxil, Mad 3 and Mad 4), Mnt/Rox, and Mga (Blackwood and Eisenman, 1991; Zervos et al., 1993; Hurlin et al., 1995 Hurlin et al., , 1997 Hurlin et al., , 1999 Meroni et al., 1997) . The dierent dimers bind to E-box sequences (5'-CACGTG-3') in promoters and regulate transcription (for review see LuÈ scher and Larsson, 1999; LuÈ scher, 2001 ). Binding of Myc/Max contributes to gene activation through the N-terminal transactivation domain (TAD) of Myc whereas Mad/ Max and Mnt/Max dimers repress transcription. Myc/ Max heterodimers activate a number of genes that are directly or indirectly involved in cell cycle progression (for review see Cole and McMahon, 1999; Amati et al., 2001; LuÈ scher, 2001) . Among the increasing number of Myc-regulated genes, the recently discovered E-box sequences in the promoter of the gene encoding the catalytic component of human telomerase, hTERT (Wu et al., 1999; Greenberg et al., 1999) , are of special interest since re-activation of telomerase is an obligatory ®nding in many human malignancies (for review see Shay and Bacchetti, 1997) . It is an attractive hypothesis that overexpressed Myc promotes cellular immortalization at least in part through reactivation of hTERT (for review see Cerni, 2000) . Indeed, myc genes are deregulated in a large number of human tumors and aect both the development and progression of hyperproliferations (see DePinho et al., 1991) .
Myc stimulates the G1-S phase transition of the cell cycle by positively modulating cyclin D/CDK (cyclin dependent kinase) and cyclin E/CDK2 complexes and by negatively regulating the CDK inhibitors p21 and p27 (for review see Amati et al., 2001; LuÈ scher, 2001 ). Conversely, cell cycle exit and cellular dierentiation are usually associated with downregulation of myc. While c-Myc normally is expressed in proliferating cells, Mad proteins are expressed in dierentiating and resting cells, and terminal dierentiation is closely linked to upregulation of mad genes Larsson et al., 1994 , Hurlin et al., 1995 VaÈ strik et al., 1995; Cultraro et al., 1997; QueÂ va et al., 1998; Pulverer et al., 2000) . Mad proteins are negative regulators of cell growth and inhibit the proliferation of a variety of human and rodent cell lines and the transformation of rat ®broblasts by cMyc/c-H-Ras and other combinations of oncoproteins (Cerni et al., 1995; Chen et al., 1995; Hurlin et al., 1995; Koskinen et al., 1995; Lahoz et al., 1994; Roussel et al., 1996; Roy and Reisman, 1995; VaÈ strik et al., 1995; QueÂ va et al., 1999; Bejarano et al., 2000; Gehring et al., 2000) . It has also been shown that Mad1 expressed from an adenoviral vector is able to inhibit the growth of a human tumor cell line transplanted into immunocompromised mice (Chen et al., 1995) . In addition, Mad1 inhibits apoptosis induced in dierent cell systems and under dierent experimental conditions (Bejarano et al., 2000; Gehring et al., 2000) . Furthermore, granulocytic progenitor cells of mice with a homozygous deletion of mad1 display extra rounds of mitotic divisions prior to terminal dierentiation. However the number of mature granulocytes is normal in these animals most likely due to enhanced apoptosis .
The repressive eect of Mad and Mnt is mediated by their N-terminal mSin3 interaction domains (SID). The mSin3 proteins in turn recruit corepressor molecules and histone deacetylases, and Mad and Mnt are therefore thought to exert their repressing activity at least in part by modi®cation of chromatin structure (Alland et al., 1997; Hassig et al., 1997; Heinzel et al., 1997; Laherty et al., 1997; Sommer et al., 1997) . The function of Myc has also been coupled to modulation of chromatin structure through its binding to the TRRAP protein which is part of a SAGA-like complex containing the histone acetyltransferase hGCN5 (McMahon et al., 1998 (McMahon et al., , 2000 Bouchard et al., 2001) . Since the Myc and Mad proteins are expressed during dierent growth conditions and have opposite eects on cell proliferation, it has been suggested that they constitute a molecular switch for proliferation versus growth arrest and/or dierentiation . According to this hypothesis, the abundance of Myc-versus Mad-containing heterodimers determines at least in part whether cells enter a dierentiation pathway or remain in a proliferative state.
To investigate the eect of Mad1 on growth of tumorigenic cells we generated c-Myc/c-H-Ras transformed rat cell lines that express an inducible Mad1 protein. These cells were used to study the eect of Mad1 activation on proliferation of the tumorigenic cells in vitro and in vivo.
Results

Generation and characterization of Mad1ER cell lines
We transfected a construct encoding a chimeric Mad1-estrogen receptor ligand binding domain (Mad1ER) into rat embryo cells (REC) together with vectors encoding c-Myc (M) and c-H-Ras (R). The generation of transformed REC is strictly dependent on the coexpression of both c-Myc and an activated Ras (Land et al., 1983; Cerni et al., 1995) . After G418 selection 50 colonies were picked and screened for Mad1 expression by immuno¯uorescence. Only two clones, MRMad1ER-5 and MRMad1ER-6, showed Mad1¯uorescence while the remaining 48 clones were negative (Figure 1a , lower panel and data not shown). In contrast, transformed control c-myc/c-H-ras cell lines (MR lines), that were not transfected with the mad1ER plasmid, did not stain with the Mad1-speci®c antibody (Figure 1a , upper panel and data not shown).
Northern blot analysis revealed that both MRMad1-ER clones expressed the chimeric mad1ER mRNA to a similar extent (Figure 1b) . For comparison four transformed control cell lines, MR-1, -2, -3, and -6 were concomitantly analysed. In all four cell lines the expression levels of exogenous c-myc were similar while the levels of ras were signi®cantly lower compared to the two Mad1ER lines (Figure 1b) . Similarly, lower levels of ras were observed in 15 additional MR lines (data not shown), suggesting that the enhanced ras expression was speci®c for the MRMad1ER lines. As in MRMad1ER cells, addition of OHT to the transformed control cell lines altered neither myc nor ras expression (Figure 1b , and data not shown). Western blot analysis demonstrated that the size of the Mad1ER fusion protein, expressed in MRMad1ER cells, was identical to that expressed in transiently transfected COS-7 cells (Figure 1c ).
Activation of Mad1ER results in repression of TERT activity
In order to examine the functionality of the activated Mad1ER fusion protein we analysed whether it would repress a known Myc target gene. It was recently found that the 5' region of the human gene encoding the catalytic domain of telomerase, hTERT, contains an array of E-box sequences and that some of these are targeted by Myc/Max and Mad1/Max complexes (Greenberg et al., 1999; Wu et al., 1999; Xu et al., 2001) . The TERT protein is the rate limiting factor for telomerase activity (Avilion et al., 1996; Ulaner et al., 1998) , and Myc expression has been shown to induce hTERT expression and activity (Wang et al., 1998; Falcetti et al., 1999) . Conversely, overexpressed Mad1 represses enzyme activity (Oh et al., 2000) . We therefore analysed the activity of the rat TERT gene in the MRMad1ER-5 cells before and after OHT induction. Although the locus of the rat TERT is not characterized at present, conserved regulation of TERT genes by c-Myc can be deduced from the identical localization of relevant E-box sequences in the murine and human TERT promoters (Greenberg et al., 1999; Wu et al., 1999) . Indeed, we have found that transfection of c-myc/c-H-ras into primary REC can induce high levels of telomerase activity (unpublished observation). The telomerase activity in MRMad1ER-5 cells was approximately 20% of that observed in HeLa cells (Figure 2a,c) . Similar results were obtained with cells that were kept for several days in ethanol, the solvent for OHT (Figure 2a, c, lanes 12 ± 14) . In contrast, OHT-treatment of the MRMad1ER-5 cells almost completely abolished telomerase activity ( Figure  2a ,c, lanes 2 ± 6). Since MR-1 cells, used throughout this study as preferential control, had a priori only low levels of endogenous telomerase activity, we instead used MR-2 cells as control. As expected, presence of OHT had no eect on telomerase activity in MR-2 cells (Figure 2b,c) . This ®nding corroborated our data that the OHT-induced Mad1ER inhibited TERT activity in the MRMad1ER-5 cells. Taken together, our results demonstrate that the transcriptional repressor function of Mad1ER is activated by OHT.
Inhibition of proliferation by Mad1ER in vitro
To examine the eect of Mad1 activation on cell proliferation, MRMad1ER cells were seeded at low cell numbers and incubated in the presence or absence of OHT for 10 days prior to staining with Giemsa. OHTinduction of Mad1 resulted in a signi®cant reduction in both the number and the size of the colonies (Figure 3 , lower panel). No in¯uence of OHT on colony formation was observed with MR-1 cells (Figure 3 , upper panel). The eect of Mad1 on cell growth was density-dependent since Mad1 did not signi®cantly inhibit colony growth when cells were seeded at high densities (data not shown).
We then performed FACS analysis in order to analyse the eect of Mad1ER on cell cycle distribution. MRMad1ER-5 cells have a diploid karyotype despite their highly transformed morphology (Figure 4a ), while MRMad1ER-6 cells are mainly tetraploid (Figure 4c ). In such heteroploid cells, the overlap of the G2/M fraction of diploid cells with the G1 fraction of tetraploid cells restricts the cell cycle analysis to cells in S phase. The fraction of cells in S phase decreased from 51 to 25% and from 58 to 43% in clone MRMad1ER-5 and -6 cells, respectively, upon activation of Mad1ER ( Cells were cultured for 7 days in 2% FCS either in the absence or presence of OHT or supplemented with the appropriate concentration of ethanol (EtOH), the solvent for OHT. Various amounts of cell lysates were subjected to PCR-based TRAP assay. The ampli®cation products were separated on a 10% nondenaturing polyacrylamide gel and stained with Vistra Green. 0.5 mg of HeLa cell extract was used for comparison. Lysis buer (LB) served as negative control. One out of three independent experiments is shown 
Activation of Mad1ER results in inhibition of Myc/Ras-dependent tumor growth
The Myc-antagonizing eects of Mad1 in the MRMad1-ER cells in vitro encouraged us to investigate whether activation of Mad1 could inhibit the in vivo growth of the cells. A small number ( 5610 4 ) of MRMad1ER-5 cells was injected into syngenic 7 day old male Fisher rats. Concomitantly animals received intraperitoneally (i.p.) OHT (0.3, 1.2, and 2.4 mg/kg) or PBS injections that were repeated every other day throughout the experiment.
On day 5 after tumor cell injection the ®rst small nodules were detected in the control, group A, that received PBS and group B that received 0.3 mg/kg OHT (Figure 5a, b) . By day 12 all animals of these two groups had palpable tumors. The tumors grew rapidly reaching diameters of 20 mm and more after a few days. Of the seven animals in group C, which were treated with 1.2 mg/kg OHT, four rats developed tumors with a similar latency period as observed in the control and group B (Figure 5c ). In three rats the ®rst palpable tumors arose after a longer latency period. However, the growth kinetic of all tumors in group C was rapid and similar to those of the tumors in groups A and B. The doubling time of tumor size in groups A, B, and C was 2 to 3 days. In the animals of group D, that were treated with 2.4 mg/kg OHT, the ®rst two tumors become detectable on day 12 after injection and only by day 19 small tumor nodules were palpable in the remainder (Figure 5d ). Thus, the average latency period of tumor appearance in this group was doubled. The initially retarded outgrowth of injected MRMad1ER cells was followed by slow tumor growth. In all but one animal the doubling time of tumor size increased signi®cantly to up to 2 weeks. Comparison of tumor growth in the four groups showed a clear dose dependent eect of OHT on the proliferation rate of MRMad1ER cells in vivo. Three slowly growing tumors of group D (animal No. 2, 4 and 6, respectively) started to grow fast after approximately 40 days which might indicate the outgrowth of a subpopulation of more aggressive tumor cells. Figure 5e summarizes the successive increase of mean tumor diameters in the various treatment groups. While low concentrations of OHT appeared rather to stimulate tumor growth, the highest OHT-concentration signi®cantly inhibited the proliferation of MRMad1ER cells in vivo. The mean values of tumor diameters between groups A and D diered signi®cantly (P50.05) on day 19 after tumor cell injection. The fact that the body mass of OHT-treated rats increased in line with solvent-treated animals ( Figure 5f ) and untreated rats (data not shown) argues against biasing side-eects of repeated i.p. injections or OHT-applications. When MRMad1ER-6 cells were injected into animals in an analogous experiment using 2.4 mg/kg OHT, an increase in latency period and a reduction of tumor growth were observed, albeit less dramatic than with the MRMad1ER-5 tumors (data not shown). This is consistent with the observed dierences in reduction of S phase cells as determined by FACS analysis (Figure 4a ± d) .
It is known that tamoxifen, a clinically applied antiestrogenic drug that is metabolized to OHT, can inhibit tumor cell growth both in vivo and in vitro in an unspeci®c manner, i.e. by mechanisms that are independent of the presence of estrogen receptors (Gundimeda et al., 1996; Treon et al., 1998; . Although in previous in vitro experiments, a series of transformed c-myc/c-H-ras cell lines were found unresponsive to OHT application in culture as determined by growth curves and FACS analysis (Figure 4e,f and data not shown), we investigated the eect of the highest OHT-concentration on the in vivo growth of MR-1 cells (Figure 6 ). For comparison with the previous animal experiments, the number of injected cells was kept constant at 5610 4 cells per rat although the low ras expression of MR-1 cells ( Figure  1b ) was suggestive of a probably reduced tumorigenicity. Indeed, one animal in each group, i.e. No. 5 in group E and No. 2 in group F, respectively, remained tumor-free. However, among the arising tumors, there was no dierence between solvent-and OHT-treated rats neither with regard to tumor onset nor growth kinetics ( Figure 6 ). Note that the in vivo proliferation of untreated MR-1 and MRMad1ER-5 cells was similar despite their dierent ras mRNA expression (Figure 1b) .
Analysis of tumor-derived cell lines
We then examined whether the in vivo passage had altered the geno-and/or phenotype of MRMad1ER cells. Of nine isolated tumors from the dierent treatment groups, seven were successfully re-established (Figure 7a,b) . We observed that OHT reduced the expression of the Mad1ER protein in some of the cell clones. The reason for this is unclear at present. Since this was also found in the parental MRMad1ER-6 cells one may speculate that this could be part of a compensatory autoregulatory mechanism to limit Mad1 activity. We also performed FACS analysis and Table 1 shows the percentage of cells in S phase in the dierent TD lines. With exception of TD-A5, the overall percentage of cells in S phase was lower than in the parental cells. Three TD lines (TD-A5, TD-B2, and TD-C6) still responded to OHT as determined by the reduction in the number of S phase cells while the other three did not. We analysed the expression of some cell cyclerelevant proteins that could be responsible for the reduction of S phase cells in presence of OHT, with special interest on the still inducible TD-cell lines. However, Mad1 did not consistently aect the expression of p27, cyclin D1, or p21 (Figure 7b and data not shown). One cell line, TD-D2, deviated from the overall picture. These cells were derived from the tumor of animal No. 2 in group D, in which tumor growth was clearly accelerated after 37 days, indicating that some prominent genetic alterations had occurred. Indeed, addition of OHT resulted in a reduction of Mad1 expression (Figure 7a) , induction of cyclin D1 (Figure 7b) , and a concomitant increase of cells in S phase (Table 1 ). These data indicate that selective pressure against Mad1-mediated growth inhibition was exerted in vivo, with TD-D2 as a clear example. 
Discussion
We have generated transformed cell lines derived from primary rat embryo cells (REC) that express the human c-myc and c-H-ras genes together with a mad1-estrogen receptor fusion construct, mad1ER. Using these cells we have analysed the eect of activated Mad1ER on cell proliferation in vitro and in vivo. Our ®ndings demonstrate that functional Mad1 can be expressed in REC concurrently with high-level expression of c-Myc and c-H-Ras and that activated Mad1 inhibited telomerase activity and proliferation of the transformed cells in vitro.
Injection of the cells into syngenic rats induced aggressively growing tumors after a short latency period. In contrast, continuous activation of Mad1 prolonged the latency period of tumor appearance and reduced the growth rate of the tumors in an OHT-dose dependent manner. These eects were speci®c for Mad1 since no eect of OHT was observed with transformed MR-1 control cells. Taken together, our results provide further evidence for a growth inhibitory role of Mad1 and extend its function to the inhibition of myc-expressing tumors.
In our attempts to generate c-myc/c-H-ras transformed REC cell lines that express the chimeric mad1ER transgene, only two out of 50 clones analysed clearly stained positive for the Mad1ER protein. One possibility for the low yield is that the primary REC used as target cells represent a mixture of dierent cell types and it is feasible that the proliferation of some (or most) might be sensitive to even low amounts of Mad1. Although the transfected REC were kept in phenol red-free medium supplemented with lowestrogen or charcoal-absorbed serum, remaining traces of estrogen in the sera might have been sucient to activate the Mad1ER fusion protein and consequently inhibit the outgrowth of potential founder cells. We have previously observed such inherent sensitivity toward low Mad1 levels in established cell lines (Gehring et al., 2000) . Another possibility is that basal Mad1 levels can be tolerated only in the presence of high c-Myc levels. Abundant Myc/Max complexes might eciently antagonize Mad/Max dimers, thereby allowing cell proliferation. In support of this hypothesis, Cultraro et al. (1997) reported that expression of Mad1 could only be obtained in the presence of c-Myc in mouse erythroleukemia cells. However, this does not seem to be the explanation in our cells since we found that the amount of c-myc mRNA in the two established MRMad1ER clones was similar to that expressed in four MR cell lines. In contrast, the former cells expressed unusually high levels of ras mRNA and protein. In this context, a recent study on the cooperation of oncogenic ras with endogenous c-myc is of interest. Bazarov et al. (2001) reported that high levels of a c-H-Ras mutant (G12V) could compensate for low c-Myc levels in anchorage-independent growth of Rat1a cells as evidenced by ecient cell growth in semi-solid medium. Thus, if low Mad1 levels in our cells compromised some of the c-Myc functions relevant for the transformed phenotype (which was the criterion for clonal isolation), then high c-H-Ras levels might have been the necessary prerequisite for clonal outgrowth. This assumption is not only supported by the high level of ras mRNA and protein (Figures 1 and 7) , but also by the stable morphology of the MRMad1ER cells and their tumor-derived cell lines, irrespective of Mad1 activation (data not shown). Furthermore, tropomyosin levels, which are high in normal,¯at REC (Figure 7b, lane 14) and generally low in their transformed derivatives remained stable in the MRMad1ER cells and their TD-lines upon OHT treatment (Figure 7b and unpublished observation) . The expression of tropomyosin has also been reported previously to decrease upon transformation (Prasad et al., 1999) . Taken together, our data indicate that Mad1 does not alter the transformed morphology of our cell lines which might be due to the high level of Ras expression.
Analysis of cell cycle distribution of the MRMad1-ER cells revealed a reduction in the cell fraction in S phase upon Mad1 activation. The cells were however not arrested since they continued to cycle, albeit at a slower rate. A decrease in the number of S phase cells was also observed in response to Mad1 expression in astrocytoma and NIH3T3 cells (Chen et al., 1995; Roussel et al., 1996) . In contrast to the modest eects during normal growth conditions, we found that Mad1 inhibited cell proliferation very eciently when the MRMad1ER cells were plated at low cell density. When the number of plated cells was increased, this eect was no longer observed. We have made similar observations demonstrating more pronounced eects of Mad1 on proliferation during restrictive growth conditions in two other model systems (Bejarano et al., 2000; Gehring et al., 2000) . These data suggest that Mad1 function is most clearly manifested under restrictive growth conditions.
To further characterize the consequences of Mad1-ER activation we studied the eect on rat telomerase activity. As anticipated, the telomerase activity of MRMad1ER-5 cells was reduced to almost undetectable levels upon addition of OHT, but remained high in the transformed control MR line under the same conditions. Similarly, we and others have recently reported reductions in telomerase expression and activity in two human tumor cell lines, U937 and HL60, in the course of drug-induced dierentiation concomitantly with Mad1 upregulation (GuÈ nes et al., 2000; Xu et al., 2001 ). In addition, hTERT expression in normal and malignant human cells was found to have an inverse correlation with Mad1 expression (Cong and Bacchetti, 2000; Oh et al., 2000; GuÈ nes et al., 2000) . The Mad1-induced repression of hTERT transcription is mediated by the N-terminal SID of Mad1 that recruits histone deacetylases to chromatin (Cong and Bacchetti, 2000) . Furthermore, there is a switch from Myc/Max to Mad1/Max binding and a decrease in histone acetylation at the hTERT promoter during HL60 dierentiation (Xu et al., 2001) . This indicates that acetylation/deacetylation of histones contributes to the regulation of hTERT expression.
The inhibition of telomerase activity in response to Mad1 might contribute to the reduced in vivo growth of MRMad1ER-5 cells. REC are equipped with up to 150 kb ultralong telomeres that further increase by transfection of c-myc and c-H-ras (unpublished observation). Nevertheless, cell proliferation could well be aected by the lack of telomerase, probably even in case of long telomeres. Besides the eect of telomerase on telomere elongation, the enzyme exerts in addition a protective capping function on the telomeric ends that is independent from synthesis of telomeric repeats (Zhu et al., 1999) . However, oncogene-transformed murine cells derived from animals without functional telomerase are as tumorigenic as their wild type counterparts, arguing against a contribution of telomerase activity for tumorigenic growth of rodent cells (Blasco et al., 1997) . Thus at present it is unclear whether telomerase inhibition upon Mad1 induction in vivo contributes to the reduced tumor growth.
Considering the complexity of cellular requirements for autonomous growth in vivo, several possibilities are conceivable for Mad1-mediated tumor inhibition. Transformed cells will not give rise to progressively growing tumors unless their survival in the host organism is guaranteed by a sucient supply of blood vessels. Since normal tissue generally produces more inhibitors than stimulators of neoangiogenesis, tumor cells must shift the balance in favor of angiogenic factors. Overexpression of c-Myc, a common ®nding in many dierent kinds of experimental and clinical malignant tumors, can suppress transcription of thrombospondin 1 (Tsp-1), a secreted inhibitor of angiogenesis (Good et al., 1990) . It was recently shown that c-myc-transformed Rat-1a ®broblasts provoke neovascularization in vivo when injected into immunode®cient mice or immunprivileged sites (Ngo et al., 2000) . It is likely that downregulation of angiogenic inhibitors such as Tsp-1 or similar factors by deregulated Myc contribute to the aggressive growth potential of myc-expressing tumor cells. Conversely, inhibition of c-Myc function by Mad1 could hamper the outgrowth of Myc expressing cells as a consequence of limited blood supply. Although determination of the nature and amount of angiogenic factors in the MRMad1ER cell lines is a future project, it is likely that the cells produce the potent angiogenic VEGF due to high c-H-ras expression (Rak et al., 1995; Larcher et al., 1996) . Since neovascularization requires a coordinated array of a multitude of distinct proteins, upregulation of angiogenesis inhibitors such as for instance Tsp-1 by compromised c-Myc function could contribute to reduced tumor growth potential.
Mad1 might also oppose some c-Myc functions relevant for cell cycle progression. However, when we compared cell cycle distribution patterns of MRMad1-ER cells and protein data from the founder and the tumor-derived cell lines, no consistent picture emerged. One explanation for our results might be that the high amounts of c-H-Ras in MRMad1ER cell lines compensated some of the Mad1-compromised c-Myc functions, analogous to the reported attachmentindependent growth of c-myc de®cient, yet c-H-ras transformed Rat1a cells (Bazarov et al., 2001) . Similar to the ®ndings reported here, we could not detect any dierences in expression of cell cycle regulatory molecules in Mad1-induced versus uninduced human tumor cells (Gehring et al., 2000) . In contrast, QueÂ va et al. (1999) reported that mouse embryo ®broblasts derived from mad1 transgenic mice displayed increased levels of p21 and p27 and reduced CDK2 and CDK4 activities. We also observed an increase in p27 expression and a reduction in CDK2 activity in Mad1-expressing NIH3T3 cells (Bejarano et al., 2000) . These data support the notion that Mad1 exerts at least some of its functions through negative regulation of CDK activity. It remains to be determined if Ras oncoproteins are able to abolish or compensate the eects of Mad1 on the activity of CDK complexes.
Recently, a number of studies have identi®ed Myc target genes involved in cell cycle regulation, cell death, immortality, matrix adhesion, protein synthesis, and metabolism (see Grandori et al., 2000; Coller et al., 2000; O'Hagan et al., 2000; Guo et al., 2001) . The generation of Rat1-derived cell lines with homozygous deletion of c-myc allels revealed new insights into cMyc functions. Comparison of gene expression between exponentially growing c-myc-null and wild type Rat1 cells identi®ed 188 genes up-regulated and 95 genes down-regulated, directly or indirectly by endogenous c-Myc (Guo et al., 2001) . However, when Rat1 cells over-expressing a c-myc transgene were analysed and compared to the wild type Rat1 cells, a smaller set of genes was found activated, with only partial overlap with the latter (Guo et al., 2001) . These data therefore suggest that endogenous c-Myc might regulate a dierent set of genes than ectopically overexpressed c-Myc. It is possible that Mad1 interferes preferentially with the genes regulated by endogenous c-Myc rather than with those induced by overexpressed oncogenic Myc. A decrease, but not complete inhibition of cells in S phase would then be expected in vitro and, in turn, result in slower tumor growth in vivo, which is what we observed.
An inverse correlation between Myc-and Mad expression was found in a series of specimens of dierently advanced human breast cancers. This correlated with the clinical stage, with high Mad1 in (Han et al., 2000) . In invasive ductal carcinoma, Myc expression was prominent in cancerous tissue and proliferating cells, while Mad expression was sporadic and restricted to non-proliferating cells.
In the more dierentiated tumor cells, Mad expression was high and found in more cells, while it was reduced in less dierentiated tumor cells. It was concluded that loss of Mad1 expression might contribute to malignant transformation of human mammary epithelial cells. These data, taken together with our results showing that activation of Mad1 in c-myc/c-H-ras transformed cells signi®cantly retarded tumor appearance and reduced tumor growth, indicates that Mad1 might play a role in preventing tumorigenesis.
Materials and methods
Plasmids and antibodies
CMVmad1, pSPmyc and pSPmax have been described previously (Cerni et al., 1995) . pSPmyc and pVZ1mad1 were obtained from L Kretzner and D Ayer, respectively. The mad1 insert of pVZ1mad1 was cloned into ERBS6 (a kind gift from J LuÈ scher-Firzla) generating mad1ER. The mad1ER insert was sequenced and cloned into pSP generating pSPmad1ER. From the plasmid pVEJB which expresses an activated c-H-ras oncogene and a neo resistance gene (Cerni et al., 1990) , the BamHI inserted neo gene was removed and the plasmid religated. pRSVneo was used as the neomycin resistance encoding plasmid (Gorman et al., 1983) . Polyclonal antibodies recognizing Mad1 (C-19), c-Myc (N-262), p27 (F-8), ER (F-10) were from Santa Cruz and the mouse monoclonal antibodies against Myc (Ab-2) and cyclin D1 (Ab-1) were obtained from Neomarkers. The 5C9 monoclonal antibody recognizing Mad1 has been described previously (Sommer et al., 1997) . Anti-tropomyosin (TM311) was from Sigma and anti-human p21 ras was obtained from Dako. DTAF-and Cy 3 -labeled secondary antibodies were from Amersham Pharmacia Biotech, and anti-mouse and anti-rabbit IgG coupled to horseradish peroxidase were obtained from Calbiochem and Amersham Pharmacia Biotech, respectively.
Cell culture and transfection
Primary rat embryo cells (REC) were obtained from 15.5 gestation day old Fischer rat embryos by fractionated trypsinization as described (Cerni et al., 1990) . REC were grown in phenol-red-free DMEM (Gibco) in 10% lowestrogen FCS (Bioconcept) and transfected with 2.5 mg pVEJB, 2.5 mg of pSPmyc, 5 mg of pSPmad1ER and 1 mg of pRSVneo per 60 mm petri dish using the calcium phosphate technique. In parallel REC were transfected with 2.5 mg pVEJB, 2.5 mg of pSPmyc and 1 mg of pRSVneo per 60 mm petri dish. Twenty hours after transfection the cells were trypsinized and replated at 3610 5 per 60 mm dish. Two days later 200 mg/ml G418 (Geneticin, Gibco) was added and the cells were fed with fresh medium containing G418 every 2 to 3 days. After 14 days colonies were picked and checked for Mad1 expression using immuno¯uorescence. Two positive clones MRMad1ER-5 and -6 were identi®ed, expanded and further characterized. Several Myc/Ras transformed clones (MR-1 etc) were also picked and expanded. The REC clones were maintained in phenol-red-free DMEM medium (Gibco) supplemented with 10% low estrogen FCS (Bioconcept) or charcoal-treated FCS (PAA, Austria) and penicillin/streptomycin (10 U/ml). 4-Hydroxy-Tamoxifen (OHT; Calbiochem) was added at a concentration of 1 mg/ml medium. HeLa cells were grown in DMEM supplemented with 10% FCS.
Immunofluorescence
Cells were grown on coverslips in the presence of OHT for 24 to 48 h, ®xed in phosphate buered saline (PBS) containing 4% paraformaldehyde, and permeabilized in PBS with 0.2% Triton X-100. Subsequently, cells were incubated in PBS containing 20% horse serum (blocking buer). Antibody stainings were performed in blocking buer. The DNA was stained with Hoechst 33258 (1 mg/ml in PBS) and the coverslips mounted with Moviol (Merck) in PBS containing 2.5% N-propylgallate (Sigma).
Northern blotting
Total RNA was isolated by Trizol (Gibco) according to the manufacturer's instructions. Ten mg of total RNA was separated on a glyoxal/dimethylsulphoxide agarose gel and blotted onto GeneScreen membranes (New England Nuclear), which were hybridized to random-primed cDNA probes of mad1, c-myc, c-H-ras and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Hybridizing mRNA was visualized by autoradiography.
Western blotting
Immunoblot analysis was performed as described previously (Bejarano et al., 2000) .
Telomeric Repeat Amplification Protocol (TRAP) assay
Cell lysates were prepared using the CHAPS detergent lysis method (Kim et al., 1994) . The protein concentration of lysates was measured using the BioRad (Bradford) protein assay. The PCR-based TRAP assay for detection of telomerase activity was performed according to Kim et al. (1994) with some modi®cations. 0.2 ± 5 mg of lysates were subjected to 25 PCR cycles. The ampli®cation products were separated on a 10% nondenaturing polyacrylamide gel, stained with Vistra Green (Amersham Life Science) and visualized in a FluorImager 595 (Molecular Dynamics) using ImageQuant 5.0. Semiquantitative densitometric evaluation was performed by ImageQuant 5.0.
Colony formation assays
Cells were seeded in petri dishes at low cell numbers (100 or 500 cells per 10 cm dish) and cultured in media containing 10% FCS in the absence or presence of OHT. After 10 days cell colonies were stained by Giemsa.
FACS analysis
Cells were seeded in 60 mm dishes in DMEM with 10% FCS and cultured for at least 24 h before induction. The cells were then incubated in FCS or charcoal-depleted FCS for at least 48 h in the absence or presence of OHT. Cells were harvested and ®xed overnight in 70% ice-cold ethanol, washed in PBS and resuspended in 1 ml PBS containing 5 mg/ml propidium iodide (Sigma) and 100 mg/ml RNaseA (Sigma). Samples were incubated for 30 min at 378C and placed at 48C before ¯ow cytometry analysis of the DNA pro®le. All samples were analysed in a Becton Dickinson FACSCalibur system using CELLQuest software.
Animal experiments
Seven-day-old male Fisher rats received into the back subcutaneous injections of 5610 4 transformed cells in PBS. OHT was dissolved in ethanol and diluted with PBS to concentrations of 3 mg/ml, 6 mg/ml, 12 mg/ml and 24 mg/ml. Since the latter contained 4% ethanol, the ethanol concentration was adjusted to 4% in the other OHT-dilutions to avoid a probably biasing variable. On day 0, animals were injected with the tumor cells followed by i.p. applications of 0.3, 0.6, 1.2, and 2.4 mg/kg OHT or PBS with 4% ethanol. Treatment was repeated every other day with freshly prepared OHT solutions. Animal weight and tumor size were monitored regularly. Animals were killed by cervical dislocation when tumor diameters were approximately 20 mm for younger and 40 mm for older rats or before an unfavorable tumor localization would have restricted rats' comfort. Mean tumor diameters were statistically compared by the Kruskal-Wallis-test using Graph Pad Prism. The animal experiment was performed according to the animal experiment approval GZ 66.009/98-Pr/4/00 given by the Austrian Ministry of Culture and Education.
Re-establishment of tumor-derived cell lines
Several tumors were excised, minced and replated in DMEM with 10% FCS without G418. A few days after explantation cells started to grow out from the tissue fragments. When small colonies had formed, cultures were carefully rinsed to remove abundant debris and¯oating tumor pieces. The morphology of attached, growing cells was indistinguishable from the initially injected cell lines. Since a ®rst set of recultured tumors underwent apoptosis upon addition of G418 to the culture medium, we omitted the selection drug thereafter. Although the phenotype of these tumor-derived (TD) lines was clearly transformed, they had obviously lost the neo resistance gene in the course of the in vivo passage.
